{"id":800770,"date":"2022-06-15T07:01:26","date_gmt":"2022-06-15T05:01:26","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/"},"modified":"2023-07-11T15:13:36","modified_gmt":"2023-07-11T13:13:36","slug":"morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/","title":{"rendered":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210"},"content":{"rendered":"Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital\n\n\nHIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210\n\n\nMorphoSys will receive a 15% equity stake in HIBio and up to $1 billion in milestone payments across programs, plus single- to low double-digit royalties on net sales\n\n\nAgreements allow MorphoSys to focus its resources on progressing its potential best-in-class, late- and mid-stage oncology pipeline\n\nPLANEGG\/MUNICH, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NAS
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49624],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-800770","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-europe"],"acf":[],"yoast_head":"\nMorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-15T05:01:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-11T13:13:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"olomaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"olomaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\"},\"author\":{\"name\":\"olomaster\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\"},\"headline\":\"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210\",\"datePublished\":\"2022-06-15T05:01:26+00:00\",\"dateModified\":\"2023-07-11T13:13:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\"},\"wordCount\":1758,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in Europe\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\",\"name\":\"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-06-15T05:01:26+00:00\",\"dateModified\":\"2023-07-11T13:13:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\",\"name\":\"olomaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"caption\":\"olomaster\"},\"url\":\"https:\/\/bebeez.it\/en\/author\/olomaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/","og_locale":"en_US","og_type":"article","og_title":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 - BeBeez","og_description":"Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed by ARCH Venture Partners and Monograph Capital HIBio obtains exclusive worldwide rights, with the exception of Greater China for felzartamab and Greater China and South Korea for MOR210 MorphoSys will receive a 15% equity stake in […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/","og_site_name":"BeBeez","article_published_time":"2022-06-15T05:01:26+00:00","article_modified_time":"2023-07-11T13:13:36+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"author":"olomaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"olomaster","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/"},"author":{"name":"olomaster","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518"},"headline":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210","datePublished":"2022-06-15T05:01:26+00:00","dateModified":"2023-07-11T13:13:36+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/"},"wordCount":1758,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in Europe"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/","name":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210 - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-06-15T05:01:26+00:00","dateModified":"2023-07-11T13:13:36+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/morphosys-and-hibio-enter-into-equity-participation-and-license-agreements-for-felzartamab-and-mor210\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518","name":"olomaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","caption":"olomaster"},"url":"https:\/\/bebeez.it\/en\/author\/olomaster\/"}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/800770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=800770"}],"version-history":[{"count":1,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/800770\/revisions"}],"predecessor-version":[{"id":892163,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/800770\/revisions\/892163"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=800770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=800770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=800770"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=800770"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=800770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}